'Renal impairment' diaporamas de présentation

OUTLINE

CONTRAST INDUCED NEPHROPATHY PRESENTING UNIT: NEPHROLOGY PRESENTER: UGWUNZE TOSAN JENNIFER DATE: 12/02/2014. OUTLINE. INTRODUCTION EPIDEMIOLOGY BASIC PRINCIPES OF CONTRAST MEDIA CONTRAST PHARMACOLOGY ETIOLOGY RISK FACTORS PATHOGENESIS RISK STRATIFICATION SCORING SYSTEM DIAGNOSIS

783 views • 53 slides

When to Conduct a Renal Impairment Study

Clinical Pharmacology Advisory Committee Meeting March 19, 2008 Rockville, MD. When to Conduct a Renal Impairment Study . Shiew-Mei Huang, Ph.D. Deputy Director Office of Clinical Pharmacology Center for Drug Evaluation and Research Food and Drug Administration

880 views • 52 slides

Anti- phospholipid Antibody Syndrome

Anti- phospholipid Antibody Syndrome. Dr Ramesh Jois Consultant Rheumatologist Fortis Hospital & Kanva Diagnostics. History. Conley (1952): Unusual clotting inhibitor causing hemorrhage in SLE. (Lupus anticoagulant, BFP-STS) Bowie (1963): Paradoxically had thrombosis.

902 views • 38 slides

Hematology/Oncology Emergencies

Hematology/Oncology Emergencies. Ali Mullah-Ali Oct 8 th , 2011. Tumor Lysis Syndrome Bleeding & Coagulation Abnormalities Anemia (neonates & older) including hemolytic Thrombocytopenia (neonates & older ) Thrombocytosis Pancytopenia Leukocytosis Fever & neutropenia Typhlitis

984 views • 38 slides

End of life care

End of life care. Dr Maelie Swanwick Consultant in Palliative Medicine Derby Hospitals NHS Foundation Trust. Principles of palliative care. Regards death as a normal process Neither hastening nor postponing death Provides relief from pain and other symptoms

1.3k views • 37 slides

Overview of Antivirals for HIV, HCV, & VZV Mechanisms of Action and Most Important Side Effects

Group A-7 Forrest Estes Nicholas Clapper Nourhene Farhat Courtney Drew Sheena Favors Arthur Iskhahov. Overview of Antivirals for HIV, HCV, & VZV Mechanisms of Action and Most Important Side Effects. Amantadine. MOA The M2 protein: A viral envelope protein.

891 views • 37 slides

SYMPTOM CONTROL IN PALLIATIVE CARE

SYMPTOM CONTROL IN PALLIATIVE CARE. OUTCOMES. TO IDENTIFY SYMPTOMS PREVALENT IN PALLIATIVE CARE. TO RECOGNISE THE RANGE OF SYMPTOM RELIEF THAT IS AVAILABLE TO CLIENTS TO EXPLORE THE VIABLE ALTERNATIVES TO COMMON APPROACHES IN SYMPTOM CONTROL. COMMON SYMPTOMS. Cancer Other

657 views • 37 slides

Childhood Haemolytic uraemic syndrome in New Zealand

528 views • 35 slides

Australasian Society of Clinical Immunology and Allergy Adverse Reactions to NSAIDs

Australasian Society of Clinical Immunology and Allergy Adverse Reactions to NSAIDs. David Henry Faculty of Medicine and Health Sciences The University of Newcastle NSW Australia. Aims of this presentation.

588 views • 33 slides

I have no financial relationship(s) to disclose relevant to my presentation.

All Fluids are bad The Liver and abdominal hypertension Julia Wendon Consultant Intensivist and Hepatologist Institute of Liver Studies Kings College Hospital London. I have no financial relationship(s) to disclose relevant to my presentation. julia.wendon@kcl.ac.uk.

592 views • 33 slides

Pharmacology

566 views • 32 slides

GOUT TREATMENT

GOUT TREATMENT. GOUT TREATMENT. Gout prevalence doubled over the last 20 yrs. Factors? - longevity - diuretic use - low dose ASA - obesity - end stage renal disease - hypertension - metabolic syndrome

689 views • 26 slides

Morbidity and Mortality December 9, 2009

Morbidity and Mortality December 9, 2009. Presented by: Stephen Miller, DO and Karla Witzke, DO. Pt history. 56 y.o. C male Hx CaP (Gleason 6, PSA 3.8) Cryoablation of prostate July 2009 Began c/o testicular and pelvic pain 2 months postoperative. Diagnosed w/UTI by PCP and given Cipro

473 views • 24 slides

Atrial Fibrillation in Patients With Renal Impairment

Atrial Fibrillation in Patients With Renal Impairment. NOACs to Prevent Stroke in NVAF and Renal Impairment. Which NOACs Rely Most on Renal Clearance?. NOAC Dose Reductions (SPAF). Evidence for Using NOACs in Patients With Kidney Disease. Renal Impairment Is Common Among AF Patients.

431 views • 24 slides

HTA-challenges in the Medical Device Industry

417 views • 23 slides

IV Cyclosporin Vs IV Steroids as Single Therapy for Severe Attacks of UC Gastroenterology 2001;120:1541-1552

IV Cyclosporin Vs IV Steroids as Single Therapy for Severe Attacks of UC Gastroenterology 2001;120:1541-1552. Matt Johnson and Dr. M. Smith. Introduction. IV Hydrocortisone has been for a long time the gold standard treatment of acute UC. Approximately 60% recover acutely within 5/7

266 views • 19 slides

Director, Myeloma Section Professor, Depts. of Lymphoma/Myeloma & Experimental Therapeutics Principal Investigator,

Moving Carfilzomib into the Front-line Setting in Multiple Myeloma : An Irreversible Trend? Discussion of Abstracts 8009, 8010, and 8011 Robert Z. Orlowski, Ph.D., M.D. Director, Myeloma Section Professor, Depts. of Lymphoma/Myeloma & Experimental Therapeutics

346 views • 18 slides

Director, Myeloma Section Professor, Depts. of Lymphoma/Myeloma & Experimental Therapeutics Principal Investigator,

Moving Carfilzomib into the Front-line Setting in Multiple Myeloma : An Irreversible Trend? Discussion of Abstracts 8009, 8010, and 8011 Robert Z. Orlowski, Ph.D., M.D. Director, Myeloma Section Professor, Depts. of Lymphoma/Myeloma & Experimental Therapeutics

318 views • 18 slides

Preoperative assessment

622 views • 17 slides

NSAIDs: Friend or Foe

NSAIDs: Friend or Foe. Non-Steroidal Anti-Inflammatory Drugs. Acetylsalicylic acid first produced by Charles Frederic Gerhardt in 1853 Not until1897 that Bayer, a drug and dye firm, began investigating its use as a less irritating version of standard salicylate medicines.

453 views • 14 slides